Synthetic DNA-encoded mAb (DMAb) technology is a novel approach for direct immunoglobulin (Ig) production and secretion of functional mAb in vivo, according to the plasmid DNA delivery into tissue where the delivered plasmid containing an encoded antibody sequence. Therefore, the DMAb strategy produces mAb in vivo, which allows for analysis that may otherwise be difficult to develop due to undesirable biophysical and biochemical sequence liabilities. Compared with the traditional mAb, DMAb therapeutic technology can be functionally equivalent with additional advantages such as expression profiles, glycosylation, as well as no reliance on in vivo tissue culture and costly or time-consuming production systems. The DMAb technology represents a novel technology for delivery and expression of a novel, simple, less frequent, cost-effective antibodies for therapeutics.
Creative Biolabs focuses on the development of multiple DMAb products that enable in vivo delivery of highly potent mAbs. With this technology, engineered and synthetic DMAb plasmids encoding IgG inserts were directly injected into the muscle and delivered intracellularly by electroporation, leading to in vivo expression and secretion of the encoded IgG.
Custom DMAb Design
Creative Biolabs provides a wide range of customized DMAb at a reasonable cost and fast turnaround time. Our experienced scientists are ready to solve difficult cloning projects, including large or toxic clones or clones with high GC content or highly repetitive sequences. Please contact us to provide details of your DMAb project, our team will contact you as soon as possible. If you wish to add any other modifications or conjugations to your DMAb, please contact us for more information.
Fig.1 Schematic of two-plasmid and single-plasmid antibody-encoding DNA cassettes for human IgG expression. (Flingai, 2016)
Please browse the target below to find the right product for you.
Associated Antigen Target
All services and products are only for lab research use, not for any clinical diagnosis or treatment.
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.LEARN MORE
Angiotensin-converting Enzyme 2 (ACE2)-CHO Cell Line Model for COVID-19: Helps researchers to further study the interaction between the receptor ACE2 and the COVID-19 virus.LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.LEARN MORE